Replies to post #237952 on Biotech Values

[DewDiligence]

COCP selects oral protease inhibitors—still in preclinical stage—for SARS-CoV-2:

https://www.globenewswire.com/news-release/2022/01/27/2374281/0/en/Cocrystal-Pharma-Selects-Two-Lead-Antiviral-Drug-Candidates-for-its-COVID-19-Oral-Drug-Program.html

COCP’s previously disclosed protease inhibitor for SARS-CoV-2, CDI-45205, is not oral.

[DewDiligence]

COCP climbs on the bird-flu bandwagon:

https://www.globenewswire.com/news-release/2024/06/20/2901632/0/en/New-Broad-Spectrum-Antiviral-Currently-in-a-Phase-2a-Clinical-Trial-in-Influenza-A-may-be-Effective-Against-the-H5N1-Avian-Influenza-Strain-Identified-in-Humans-Exposed-to-Infected.html